Journal News

There's more to cholesterol than meets the eye

When it comes to a role in glaucoma, it’s all about location, location, location
Sarah May
March 22, 2022

Glaucoma sometimes is called the silent thief in the night, because the eye can be damaged irreversibly before a person experiences any vision loss.

In a healthy eye, tissue called trabecular meshwork controls pressure by draining aqueous humor, the clear fluid filling the space between the cornea and lens. This drainage system clogs up in glaucoma, fluid builds up and the resulting pressure damages the optic nerve that sends visual signals to the brain. In severe cases, the eyes can bulge out.

Glaucoma damages the optic nerve and is a primary cause of irreversible blindness.
Glaucoma damages the optic nerve and is a primary cause of irreversible blindness.

Understanding how trabecular meshwork cells sense and respond to elevated eye pressure — a type of mechanical stress — is a major goal of researchers in David Križaj’s laboratory at the University of Utah. They study a mechanotransducer, a protein that senses and responds to mechanical stress, called transient receptor potential vanilloid 4, or TRPV4. When activated in trabecular meshwork, TRPV4 promotes aqueous humor drainage.

Previously, the researchers reported that a known risk factor for glaucoma, cholesterol, activates TRPV4 in retinal glia cells, which are at the back of the eye. Now, in a recent article published in the Journal of Lipid Research, Monika Lakk and colleagues report that cholesterol depletion activates TRPV4 in trabecular meshwork cells at the front of the eye — an unexpected result.

“Cholesterol has been public enemy No. 1 in the eye of the public for a long time due to its dysregulation in cardiovascular, neurologic and metabolic disease, and has been shown to subserve multiple types of inherited and acquired vision loss,” Lakk said.

On the other hand, cholesterol plays a crucial role in maintaining homeostasis. The finding that cholesterol regulates TRPV4 in opposite ways depending on its location (front versus back of the eye) demonstrates this complexity. “Clinical solutions may require a thorough understanding of the local biomechanical and cellular context,” Lakk said.

According to the researchers, increased membrane cholesterol in trabecular meshwork cells may dampen the mechanical stress signals caused by high blood pressure and prevent overstimulation of TRPV4 — a protective mechanism that may become dysfunctional in glaucoma.

By just stretching the trabecular meshwork cells — simulating what happens with glaucoma — the researchers were able to deplete membrane cholesterol, which activates TRPV4.

“This study was an exercise in surprise,” Lakk said. “We were completely unprepared for the finding that membrane lipid composition itself is a function of the biomechanical milieu.”

When a person experiences chronic stress due to conditions such as heart disease and glaucoma, she explained, “The cellular remodeling that takes place may involve the entire body and a myriad of processes and mechanisms that may flow under the radar of investigators focusing on immediate targets.”

The researchers have knocked out the TRPV4 gene in multiple eye cell types in mice and are investigating how these cells, which are unable to sense and respond to mechanical stress, affect eye fluid pressure and vision. Since cholesterol can turn TRPV4 on or off in different parts of the eye, their research suggests that glaucoma patients may benefit from carefully balanced diet regimens.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Sarah May

Sarah May is a scientific writer at the University of Chicago.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Hope for a cure hangs on research
Essay

Hope for a cure hangs on research

July 17, 2025

Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson’s fight for survival and hope. Without funding, science can’t “catch up” to help the patients who need it most.

Before we’ve lost what we can’t rebuild: Hope for prion disease
Feature

Before we’ve lost what we can’t rebuild: Hope for prion disease

July 15, 2025

Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal — and just getting started.

Defeating deletions and duplications
News

Defeating deletions and duplications

July 11, 2025

Promising therapeutics for chromosome 15 rare neurodevelopmental disorders, including Angelman syndrome, Dup15q syndrome and Prader–Willi syndrome.

Using 'nature’s mistakes' as a window into Lafora disease
Feature

Using 'nature’s mistakes' as a window into Lafora disease

July 10, 2025

After years of heartbreak, Lafora disease families are fueling glycogen storage research breakthroughs, helping develop therapies that may treat not only Lafora but other related neurological disorders.

Cracking cancer’s code through functional connections
News

Cracking cancer’s code through functional connections

July 2, 2025

A machine learning–derived protein cofunction network is transforming how scientists understand and uncover relationships between proteins in cancer.

Gaze into the proteomics crystal ball
In-person Conference

Gaze into the proteomics crystal ball

July 1, 2025

The 15th International Symposium on Proteomics in the Life Sciences symposium will be held August 17–21 in Cambridge, Massachusetts.